Eupraxia Pharmaceuticals (EPRX) Non Operating Interest Expenses (2023 - 2024)
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Non Operating Interest Expenses (2023 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.72 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.56 Bn | 58.38 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.87 Bn | 52.73 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.20 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.54 Bn | 27.70 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 306.06 Mn | 306.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -137.00 |
| Sep 30, 2024 | -451.00 |
| Jun 30, 2024 | -281,845.00 |
| Mar 31, 2024 | -321,140.00 |
| Dec 31, 2023 | -256,460.00 |
| Sep 30, 2023 | -320,466.00 |
| Jun 30, 2023 | -301,770.00 |
| Mar 31, 2023 | -291,477.00 |